(Sharecast News) - Drugmaker Hikma Pharmaceuticals lowered its medium-term margin expectations for its injectables division on Thursday, as part of its third-quarter trading update.
Hikma now expects injectables margins to settle around 30%, down from a previous range in the mid-30s. It also cut its medium-term group revenue growth forecast to...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE